Pituitary centers of excellence

Neurosurgery

Volumn 71, Issue 5, 2012, Pages 916-924

  McLaughlin, Nancy ^a   Laws, Edward R ^b   Oyesiku, Nelson M ^c   Katznelson, Laurence ^d   Kelly, Daniel F ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Center of excellence; Endonasal endoscopic surgery; Multidisciplinary treatment; Pituitary adenoma; Training; Transsphenoidal surgery

Indexed keywords

ACCREDITATION; CANCER RADIOTHERAPY; CENTER OF EXCELLENCE; CLINICAL FEATURE; ENDOSCOPIC SURGERY; HUMAN; HYPOPHYSIS ADENOMA; HYPOPHYSIS DISEASE; HYPOPHYSIS TUMOR; MEDICAL EDUCATION; MEDICAL SOCIETY; NEUROENDOCRINE DISEASE; NEUROENDOCRINOLOGY; NEUROSURGERY; NONHUMAN; PATIENT CARE; PHYSICIAN; PREVALENCE; PRIORITY JOURNAL; RADIODIAGNOSIS; RADIOSURGERY; REVIEW; TRANSSPHENOIDAL SURGERY; VALIDATION PROCESS;

HEALTH SERVICES; HISTORY, 20TH CENTURY; HUMANS; INTERNSHIP AND RESIDENCY; NEUROSURGERY; PITUITARY DISEASES; PITUITARY GLAND;

EID: 84868204298     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/NEU.0b013e31826d5d06     Document Type: Review

References (95)

1. Couper MP, Singer E, Levin CA, Fowler FJ Jr, Fagerlin A, Zikmund-Fisher BJ. Use of the Internet and ratings of information sources for medical decisions: results from the DECISIONS survey. Med Decis Making. 2010;30(5 suppl): 106S-114S.
2. Ilic D. The role of the internet on patient knowledge management, education, and decision-making. Telemed J E Health. 2010;16(6):664-669.
3. Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML, McCutcheon IE. The prevalence of pituitary adenomas: a systematic review. Cancer. 2004;101(3): 613-619.
4. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab. 2006;91(12):4769-4775.
5. Fontana E, Gaillard R. Epidemiology of pituitary adenoma: results of the first Swiss study [in French]. Rev Med Suisse. 2009; 5 (223) 2172-2174.
6. Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf). 2010;72(3):377-382.
7. Hemminki K, Försti A, Ji J. Incidence and familial risks in pituitary adenoma and associated tumors. Endocr Relat Cancer. 2007;14(1):103-109.
8. Raappana A, Koivukangas J, Ebeling T, Pirilä T. Incidence of pituitary adenomas in Northern Finland in 1992-2007. J Clin Endocrinol Metab. 2010;95(9):4268-4275.
9. McDowell BD, Wallace RB, Carnahan RM, Chrischilles EA, Lynch CF, Schlechte JA. Demographic differences in incidence for pituitary adenoma. Pituitary. 2011;14(1):23-30.
10. Biermasz NR, van Thiel SW, Pereira AM, et al. Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess. J Clin Endocrinol Metab. 2004;89(11):5369-5376.
11. Hammer GD, Tyrrell JB, Lamborn KR, et al. Transsphenoidal microsurgery for Cushing's disease: initial outcome and long-term results. J Clin Endocrinol Metab. 2004;89(12):6348-6357.
12. Lindholm J, Juul S, Jørgensen JO, et al. Incidence and late prognosis of cushing's syndrome: a population-based study. J Clin Endocrinol Metab. 2001;86(1):117-123.
13. van Aken MO, Pereira AM, Biermasz NR, et al. Quality of life in patients after long-term biochemical cure of Cushing's disease. J Clin Endocrinol Metab. 2005; 90(6):3279-3286.
14. Heald AH, Ghosh S, Bray S, et al. Long-term negative impact on quality of life in patients with successfully treated Cushing's disease. Clin Endocrinol (Oxf). 2004; 61(4):458-465.
15. Lindsay JR, Nansel T, Baid S, Gumowski J, Nieman LK. Long-term impaired quality of life in Cushing's syndrome despite initial improvement after surgical remission. J Clin Endocrinol Metab. 2006;91(2):447-453.
16. Laws ER, Jane JA Jr. Pituitary tumors\long-term outcomes and expectations. Clin Neurosurg. 2001;48:306-319.
17. Johnson MD, Woodburn CJ, Vance ML. Quality of life in patients with a pituitary adenoma. Pituitary. 2003;6(2):81-87.
18. Hamilton JJ, Fisher SE. Centers of excellence: an evolving concept\and controversy. Bull AAOS. 2006;54(1).
19. Weisman CS, Squires GL. Women's health centers: are the National Centers of Excellence in Women's Health a new model? Womens Health Issues. 2000;10(5): 248-255.
20. Champion JK, Pories WJ. Centers of excellence for bariatric surgery. Surg Obes Relat Dis. 2005;1(2):148-151.
21. Hollenbeak CS, Rogers AM, Barrus B, Wadiwala I, Cooney RN. Surgical volume impacts bariatric surgery mortality: a case for centers of excellence. Surgery. 2008; 144(5):736-743.
22. Kohn GP, Galanko JA, Overby DW, Farrell TM. High case volumes and surgical fellowships are associated with improved outcomes for bariatric surgery patients: a justification of current credentialing initiatives for practice and training. J Am Coll Surg. 2010;210(6):909-918.
23. Pratt GM, McLees B, Pories WJ. The ASBS Bariatric Surgery Centers of Excellence program: a blueprint for quality improvement. Surg Obes Relat Dis. 2006;2(5):497-503; discussion 503.
24. DeMaria EJ, Pate V, Warthen M, Winegar DA. Baseline data from American Society for Metabolic and Bariatric Surgery-designated Bariatric Surgery Centers of Excellence using the Bariatric Outcomes Longitudinal Database. Surg Obes Relat Dis. 2010;6(4):347-355.
25. Jurkovich GJ, Mock C. Systematic review of trauma system effectiveness based on registry comparisons. J Trauma. 1999;47(3 suppl):S46-S55.
26. Mann NC, Mullins RJ, MacKenzie EJ, Jurkovich GJ, Mock CN. Systematic review of published evidence regarding trauma system effectiveness. J Trauma. 1999;47(3 suppl):S25-S33.
27. Kelly DF, Becker DP. Advances in management of neurosurgical trauma: USA and Canada. World J Surg. 2001;25(9):1179-1185.
28. Sampalis JS, Denis R, Lavoie A, et al. Trauma care regionalization: a process-outcome evaluation. J Trauma. 1999;46(4):565-579.
29. Chiara O, Cimbanassi S. Organized trauma care: does volume matter and do trauma centers save lives. Curr Opin Crit Care. 2003;9(6):510-514.
30. Alberts MJ, Hademenos G, Latchaw RE, et al. Recommendations for the establishment of primary stroke centers. Brain Attack Coalition. JAMA. 2000; 283(23):3102-3109.
31. Alberts MJ, Latchaw RE, Selman WR, et al; Brain Attack Coalition. Recommendations for comprehensive stroke centers: a consensus statement from the Brain Attack Coalition. Stroke. 2005;36(7):1597-1616.
32. Lichtman JH, Allen NB, Wang Y, Watanabe E, Jones SB, Goldstein LB. Stroke patient outcomes in US hospitals before the start of the Joint Commission Primary Stroke Center certification program. Stroke. 2009;40(11):3574-3579.
33. Lichtman JH, Jones SB, Wang Y, Watanabe E, Leifheit-Limson E, Goldstein LB. Outcomes after ischemic stroke for hospitals with and without Joint Commission-certified primary stroke centers. Neurology. 2011;76(23):1976-1982.
34. Fatemi N, Dusick JR, de Paiva Neto MA, Kelly DF. The endonasal microscopic approach for pituitary adenomas and other parasellar tumors: a 10-year experience. Neurosurgery. 2008;63(4 suppl 2):244-256; discussion 256.
35. Fatemi N, Dusick JR, Mattozo C, et al. Pituitary hormonal loss and recovery after transsphenoidal adenoma removal. Neurosurgery. 2008;63(4):709-718; discussion 718-719.
36. Schaberg MR, Anand VK, Schwartz TH, Cobb W. Microscopic versus endoscopic transnasal pituitary surgery. Curr Opin Otolaryngol Head Neck Surg. 2010;18(1):8-14.
37. Jane JA Jr, Han J, Prevedello DM, Jagannathan J, Dumont AS, Laws Jr. E.R. Perspectives on endoscopic transsphenoidal surgery. Neurosurg Focus. 2005;19(6):E2.
38. O'Malley BW Jr, Grady MS, Gabel BC, et al. Comparison of endoscopic and microscopic removal of pituitary adenomas: single-surgeon experience and the learning curve. Neurosurg Focus. 2008;25(6):E10.
39. Zada G, Du R, Laws Jr. E.R. Defining the "edge of the envelope": patient selection in treating complex sellar-based neoplasms via transsphenoidal versus open craniotomy. J Neurosurg. 2011;114(2):286-300.
40. Dehdashti AR, Ganna A, Karabatsou K, Gentili F. Pure endoscopic endonasal approach for pituitary adenomas: early surgical results in 200 patients and comparison with previous microsurgical series. Neurosurgery. 2008;62(5):1006-1015; discussion 1015-1017.
41. Dehdashti AR, Gentili F. Current state of the art in the diagnosis and surgical treatment of Cushing disease: early experience with a purely endoscopic endonasal technique. Neurosurg Focus. 2007;23(3):E9.
42. Cappabianca P, Cavallo LM, de Divitiis O, Solari D, Esposito F, Colao A. Endoscopic pituitary surgery. Pituitary. 2008;11(4):385-390.
43. Kassis S, De Battista JC, Raverot G, et al. Endoscopy versus microsurgery: results in a consecutive series of nonfunctioning pituitary adenomas [in French]. Neurochirurgie. 2009;55(6):607-615.
44. D'Haens J, Van Rompaey K, Stadnik T, Haentjens P, Poppe K, Velkeniers B. Fully endoscopic transsphenoidal surgery for functioning pituitary adenomas: a retrospective comparison with traditional transsphenoidal microsurgery in the same institution. Surg Neurol. 2009;72(4):336-340.
45. Tabaee A, Anand VK, Barrón Y, et al. Endoscopic pituitary surgery: a systematic review and meta-analysis. J Neurosurg. 2009;111(3):545-554.
46. Rotenberg B, Tam S, Ryu WH, Duggal N. Microscopic versus endoscopic pituitary surgery: a systematic review. Laryngoscope. 2010;120(7):1292-1297.
47. Higgins TS, Courtemanche C, Karakla D, et al. Analysis of transnasal endoscopic versus transseptal microscopic approach for excision of pituitary tumors. Am J Rhinol. 2008;22(6):649-652.
48. Manjila S, Wu OC, Khan FR, Khan MM, Arafah BM, Selman WR. Pharmacological management of acromegaly: a current perspective. Neurosurg Focus. 2010;29(4):E14.
49. Chanson P. Emerging drugs for acromegaly. Expert Opin Emerg Drugs. 2008; 13(2):273-293.
50. Casanueva FF, Molitch ME, Schlechte JA, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf). 2006; 65(2):265-273.
51. Ascoli P, Cavagnini F. Hypopituitarism. Pituitary. 2006;9(4):335-342.
52. Auernhammer CJ, Vlotides G. Anterior pituitary hormone replacement therapy\a clinical review. Pituitary. 2007;10(1):1-15.
53. de Paiva Neto MA, Vandergrift A, Fatemi N, et al. Endonasal transsphenoidal surgery and multimodality treatment for giant pituitary adenomas. Clin Endocrinol (Oxf). 2010;72(4):512-519.
54. Jane JA Jr, Vance ML, Woodburn CJ, Laws Jr. E.R. Stereotactic radiosurgery for hypersecreting pituitary tumors: part of a multimodality approach. Neurosurg Focus. 2003;14(5):e12.
55. Jensen R, O'Rourke D, Warnick R, Sawaya R. Resident training in neurosurgical oncology: results of the survey of North American training programs by the AANS/CNS Section on Tumors. J Neurooncol. 2006;77(3):241-246.
56. Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009;94(5):1509-1517.
57. McLaughlin N, Kassam AB, Prevedello DM, Kelly DF. Management of Cushing's disease after failed surgery\a review. Can J Neurol Sci. 2011;38(1):12-21.
58. Sheehan JM, Vance ML, Sheehan JP, Ellegala DB, Laws Jr. E.R. Radiosurgery for Cushing's disease after failed transsphenoidal surgery. J Neurosurg. 2000;93(5): 738-742.
59. Garré ML, Cama A. Craniopharyngioma: modern concepts in pathogenesis and treatment. Curr Opin Pediatr. 2007;19(4):471-479.
60. Behbehani RS, McElveen T, Sergott RC, Andrews DW, Savino PJ. Fractionated stereotactic radiotherapy for parasellar meningiomas: a preliminary report of visual outcomes. Br J Ophthalmol. 2005;89(2):130-133.
61. Kontogeorgos G. Classification and pathology of pituitary tumors. Endocrine. 2005;28(1):27-35.
62. Saeger W, Lüdecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol. 2007;156(2):203-216.
63. Zada G, Woodmansee WW, Ramkissoon S, Amadio J, Nose V, Laws Jr. E.R. Atypical pituitary adenomas: incidence, clinical characteristics, and implications. J Neurosurg. 2011;114(2):336-344.
64. Galland F, Lacroix L, Saulnier P, et al. Differential gene expression profiles of invasive and non-invasive non-functioning pituitary adenomas based on micro-array analysis. Endocr Relat Cancer. 2010;17(2):361-371.
65. Evans CO, Young AN, Brown MR, Brat DJ, Parks JS, Neish AS, Oyesiku NM. Novel patterns of gene expression in pituitary adenomas indentified by complementary deoxyribonucleic acid microarrays and quantitative RT-PCR. J Clin Endocrinol Metab. 2001;86(7):3097-3107.
66. Moreno CS, Evans CO, Zhan X, Okor M, Desiderio DM, Oyesiku NM. Novel molecular signaling and classification in human clinically non-functional pituitary adenomas identified by gene expression profiling and proteomics analyses. Cancer Res. 2005;65(22):10214-10222.
67. Bush ZM, Longtine JA, Cunningham T, et al. Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression. J Clin Endocrinol Metab. 2010;95(11):E280-E290.
68. Syro LV, Ortiz LD, Scheithauer BW, et al. Treatment of pituitary neoplasms with temozolomide: a review. Cancer. 2011;117(3):454-462.
69. Gejman R, Swearingen B, Hedley-Whyte ET. Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas. Hum Pathol. 2008;39(5):758-766.
70. Salehi F, AgurA, Scheithauer BW, Kovacs K,Lloyd RV, Cusimano M. Biomarkers of pituitary neoplasms: a review (Part II). Neurosurgery. 2010;67(6):1790-1798.
71. Yamada S, Aiba T, Takada K, et al. Retrospective analysis of long-term surgical results in acromegaly: preoperative and postoperative factors predicting outcome. Clin Endocrinol (Oxf). 1996;45(3):291-298.
72. Gittoes NJ, Sheppard MC, Johnson AP, Stewart PM. Outcome of surgery for acromegaly\the experience of a dedicated pituitary surgeon. QJM. 1999;92(12): 741-745.
73. Erturk E, Tuncel E, Kiyici S, Ersoy C, Duran C, Imamoglu S. Outcome of surgery for acromegaly performed by different surgeons: importance of surgical experience. Pituitary. 2005;8(2):93-97.
74. Bates PR, Carson MN, Trainer PJ, Wass JA. Wide variation in surgical outcomes for acromegaly in the UK. Clin Endocrinol (Oxf). 2008;68(1): 136-142.
75. Shahlaie K, McLaughlin N, Kassam AB, Kelly DF. The role of outcomes data for assessing the expertise of a pituitary surgeon. Curr Opin Endocrinol Diabetes Obes. 2010;17(4):369-376.
76. Swearingen B. Update on pituitary surgery. J Clin Endocrinol Metab. 2012;97(4): 1073-1081.
77. Ciric I, Ragin A, Baumgartner C, Pierce D. Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience. Neurosurgery. 1997;40(2):225-236; discussion 236-237.
78. Barker FG 2nd, Klibanski A, Swearingen B. Transsphenoidal surgery for pituitary tumors in the United States, 1996-2000: mortality, morbidity, and the effects of hospital and surgeon volume. J Clin Endocrinol Metab. 2003;88(10): 4709-4719.
79. Barker FG 2nd. Craniotomy for the resection of metastatic brain tumors in the U.S., 1988-2000: decreasing mortality and the effect of provider caseload. Cancer. 2004;100(5):999-1007.
80. Ahmed S, Elsheikh M, Stratton IM, Page RC, Adams CB, Wass JA. Outcome of transsphenoidal surgery for acromegaly and its relationship to surgical experience. Clin Endocrinol (Oxf). 1999;50(5):561-567.
81. Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002;346(15):1128-1137.
82. Barker FG 2nd, Curry WT Jr, Carter BS. Surgery for primary supratentorial brain tumors in the United States, 1988 to 2000: the effect of provider caseload and centralization of care. Neuro Oncol. 2005;7(1):49-63.
83. Laws ER Jr, Fode NC, Redmond MJ. Transsphenoidal surgery following unsuccessful prior therapy. An assessment of benefits and risks in 158 patients. J Neurosurg. 1985;63(6):823-829.
84. Mattozo CA, Dusick JR, Esposito F, et al. Suboptimal sphenoid and sellar exposure: a consistent finding in patients treated with repeat transsphenoidal surgery for residual endocrine-inactive macroadenomas. Neurosurgery. 2006;58(5): 857-865; discussion 857-865.
85. Saeki N, Yamaura A, Numata T. Transsphenoidal reoperations for removal of pituitary adenomas: rhinological management and timing of reoperation. J Clin Neurosci. 1999;6(5):385-388.
86. Jane JA Jr, Laws Jr. E.R. The surgical management of pituitary adenomas in a series of 3,093 patients. J Am Coll Surg. 2001;193(6):651-659.
87. Wilson CB. Surgical management of pituitary tumors. J Clin Endocrinol Metab. 1997;82(8):2381-2385.
88. Jane JA Jr, Sulton LD, Laws Jr. E.R. Surgery for primary brain tumors at United States academic training centers: results from the Residency Review Committee for neurological surgery. J Neurosurg. 2005;103(5):789-793.
89. Koc K, Anik I, Ozdamar D, Cabuk B, Keskin G, Ceylan S. The learning curve in endoscopic pituitary surgery and our experience. Neurosurg Rev. 2006;29(4): 298-305; discussion 305.
90. Snyderman C, Kassam A, Carrau R, Mintz A, Gardner P, Prevedello DM. Acquisition of surgical skills for endonasal skull base surgery: a training program. Laryngoscope. 2007;117(4):699-705.
91. Lee TT, Klose JL. Survey on neurosurgery subspecialty fellowship training. Congress of Neurological Surgeons Education Committee. Surg Neurol. 1999;52 (6):641-644; discussion 644-645.
92. Wass JA, Turner HE, Adams CB. The importance of locating a good pituitary surgeon. Pituitary. 1999;2(1):51-54.
93. Clayton RN. How many surgeons to operate on acromegalic patients? Clin Endocrinol (Oxf). 1999;50(5):557-559.
94. Clayton RN, Stewart PM, Shalet SM, Wass JA. Pituitary surgery for acromegaly. Should be done by specialists. BMJ. 1999;319(7210):588-589.
95. Luft HS, Bunker JP, Enthoven AC. Should operations be regionalized? The empirical relation between surgical volume and mortality. N Engl J Med. 1979;301 (25):1364-1369.